TENX Stock Price, Tenax Therapeutics Inc Quote, Chart

Market Summary

USD3.550.00

Market Closed

0.00%

TENX Stock Price

View Fullscreen

TENX RSI Chart

TENX Valuation

Market Cap

7.0M

Price/Earnings (Trailing)

0.67

Price/Sales (Trailing)

0.5

Price/Free Cashflow

-1.18

TENX Price/Sales (Trailing)

TENX Profitability

Return on Equity

83.7%

Return on Assets

71.94%

Free Cashflow Yield

-84.92%

TENX Fundamentals

TENX Revenue

Revenue (TTM)

13.9M

Rev. Growth (Qtr)

-97.85%

TENX Earnings

Earnings (TTM)

10.4M

Earnings Growth (Yr)

370.04%

Earnings Growth (Qtr)

-33.8%

Breaking Down TENX Revenue

Last 7 days

-1.1%

Last 30 days

-1.1%

Last 90 days

-14.5%

Trailing 12 Months

-85.4%

How does TENX drawdown profile look like?

TENX Financial Health

Current Ratio

7.12

TENX Investor Care

Buy Backs (1Y)

91.01%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	7.0M	9.3M	11.6M	13.9M
2015	0	49.3K	4.7M	0
2014	444.9K	263.0K	0	0
2013	1.1M	1.2M	1.1M	625.5K
2012	346.3K	381.1K	593.7K	1.0M
2011	0	104.1K	156.6K	224.7K
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Tenax Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 21, 2022	rich stuart	gifted	-	-	1,909,580	chief medical officer
Sep 21, 2022	rich stuart	gifted	-	-	-1,909,580	chief medical officer
Aug 11, 2022	doogan declan	gifted	-	-	-567,871	-
Aug 11, 2022	doogan declan	gifted	-	-	567,871	-
Nov 29, 2021	rich stuart	gifted	-	-	1,909,580	chief medical officer
Nov 29, 2021	rich stuart	gifted	-	-	-1,909,580	chief medical officer
Oct 12, 2021	rich stuart	gifted	-	-	1,909,580	chief medical officer
Oct 12, 2021	rich stuart	gifted	-	-	-1,909,580	chief medical officer
Jun 30, 2021	doogan declan	gifted	-	-	-567,871	-
Jun 11, 2021	davidson michael h.	acquired	-	-	512,000	-

Which funds bought or sold TENX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	sold off	-100	-26,105	-	-%
May 15, 2024	MORGAN STANLEY	sold off	-100	-5,678	-	-%
May 15, 2024	MORGAN STANLEY	new	-	1,102	1,102	-%
May 15, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-1,253	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	new	-	2,277	2,277	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	sold off	-100	-39,095	-	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-13,883	-	-%
May 14, 2024	Qube Research & Technologies Ltd	sold off	-100	-137	-	-%
May 14, 2024	Qube Research & Technologies Ltd	new	-	18,686	18,686	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	sold off	-100	-93,000	-	-%

Are Funds Buying or Selling TENX?

Are funds buying TENX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TENX

No. of Funds

Unveiling Tenax Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 20, 2024	s.h.n. financial investments ltd.	5.6%	107,000	SC 13G
Feb 16, 2024	cvi investments, inc.	9.9%	204,027	SC 13G
Feb 15, 2024	lind global fund ii lp	9.9%	71,500	SC 13G
Feb 14, 2024	armistice capital, llc	0.07%	17,241	SC 13G/A
Feb 14, 2023	armistice capital, llc	9.99%	4,960,728	SC 13G/A
Feb 13, 2023	intracoastal capital, llc	4.99%	479,733	SC 13G
Feb 09, 2023	rich stuart	2.32%	215,303	SC 13D/A
Feb 09, 2023	doogan declan	1.96%	181,894	SC 13D/A
Jan 06, 2023	rich stuart	9.38%	215,303	SC 13D/A
Jan 06, 2023	doogan declan	7.94%	181,894	SC 13D/A

Recent SEC filings of Tenax Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 12, 2024	EFFECT	EFFECT
Apr 12, 2024	EFFECT	EFFECT
Apr 11, 2024	POS AM	POS AM
Apr 11, 2024	POS AM	POS AM
Mar 28, 2024	10-K	Annual Report

Peers (Alternatives to Tenax Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.57	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Tenax Therapeutics Inc News

Latest updates

Tenax Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2015Q3	2015Q2	2015Q2	2014Q2	2014Q1	2013Q4	2013Q3	2013Q2	2013Q1	2012Q4	2012Q3	2012Q2	2012Q1	2011Q4	2011Q3	2011Q2	2011Q1
Revenue	-0.9%	13,530	13,652	13,774	13,897	11,126	8,355	5,584	2,813	42.00	56.00	166	182	222	515	272	78.00	148	95.00	59.00	43.00	27.00
Gross Profit	-	-	-	-	-	-	-	-	-133	180*	21.00	8.00	37.00	1.00	5.00	6.00	5.00	2.00	17.00	25.00	44.00	27.00
Operating Expenses	57.8%	3,341	2,117	1,236	1,539	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	56.1%	1,642	1,052	1,038	1,274	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	59.4%	1,699	1,066	198	266	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-59.6%	2.00	5.00	9.00	7.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	191.0%	5,739	1,972	-1,106	-1,406	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income Margin	-42.9%	0.37*	0.65*	0.92*	0.97*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	43.5%	-1,176	-2,082	-924	-1,726	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	23.8%	14,460	11,685	11,889	14,045	15,272	3,405	4,739	8,355	3,738	5,992	8,912	2,885	4,561	6,869	8,997	5,353	5,955	6,365	7,774	9,664	11,457
Current Assets	23.8%	14,459	11,684	11,883	14,039	15,265	3,208	4,514	8,102	3,456	5,689	8,583	2,532	4,518	6,796	8,897	5,214	5,798	6,181	7,562	9,425	11,191
Cash Equivalents	28.2%	12,549	9,792	11,141	13,394	14,415	2,124	3,806	7,229	2,869	5,584	8,354	1,671	3,537	6,250	8,236	4,085	4,359	4,906	6,649	8,407	10,322
Net PPE	-	-	-	5.00	6.00	6.00	7.00	10.00	11.00	12.00	7.00	6.00	6.00	5.00	6.00	3.00	4.00	5.00	7.00	8.00	9.00	10.00
Liabilities	-43.4%	2,031	3,587	602	824	989	1,912	785	1,572	2,131	1,748	1,673	1,414	1,465	2,243	1,593	2,324	2,536	2,593	1,237	1,044	1,117
Current Liabilities	-43.4%	2,031	3,587	602	824	984	1,848	690	1,446	1,976	1,564	1,461	1,175	1,434	2,119	1,379	2,187	2,505	2,532	1,129	938	1,014
Shareholder's Equity	53.5%	12,430	8,098	11,287	13,222	14,278	1,493	3,954	6,784	1,606	4,245	7,239	1,471	3,096	4,626	7,404	3,029	3,419	3,772	6,537	10,340	10,340
Retained Earnings	-1.3%	-301,051	-297,252	-294,027	-292,055	-290,948	-289,542	-286,993	-284,076	-281,215	-278,494	-275,283	-271,484	-269,767	-246,019	-243,190	-240,969	-238,823	-236,168	-233,376	-231,153	-229,391
Additional Paid-In Capital	2.7%	313,481	305,351	305,311	305,274	305,224	291,035	290,944	290,858	282,819	282,736	282,520	272,954	272,863	250,644	250,592	243,996	242,242	239,940	239,911	239,771	239,729
Shares Outstanding	-	1,958	-	23,862	23,862	21,777	-	29,980	1,260	1,260	1,260	1,260	1,261	748	12,619	-	-	-	-	-	-	-
Float	-	-	-	-	7,031	-	-	-	5,005	-	-	-	30,559	-	-	-	9,100	-	-	-	9,167	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	43.6%	-1,174	-2,081	-922	-1,724	-1,688	-3,330	-3,431	-2,937	-2,768	-3,021	-1,845	-3,221	-1,987	-2,385	-2,228	-2,671	-1,726	-1,782	-1,914	-2,132	-1,197
Share Based Compensation	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	53.00
Cashflow From Investing	-	-	-	2.00	1.00	4.00	-	-	-6.32	-1.70	512	-20.27	-36.96	4.00	3.00	20.00	-6.33	-16.75	24.00	-204*	-8.80	1,311
Cashflow From Financing	-1.9%	-174	-171	-99.91	14,015	2.00	-91.87	7,792	229	-	9,193	-	545	-1.35	6,533	1,935	2,130	-	-	-	97.00	8,907

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TENX Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses
General and administrative	$ 1,232,674	$ 1,273,730
Research and development	2,675,652	265,735
Total operating expenses	3,908,326	1,539,465
Net operating loss	3,908,326	1,539,465
Interest expense	7,963	7,350
Other expense (income), net	(117,449)	(140,055)
Net loss	$ 3,798,840	$ 1,406,760
Net loss per share, basic and diluted	$ (3.12)	$ (12.10)
Weighted average number of common shares outstanding, basic and diluted	1,219,139	116,259

TENX Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Cash and cash equivalents	$ 12,549,475	$ 9,792,130
Prepaid expenses	1,843,047	1,639,797
Other current assets	66,625	251,583
Total current assets	14,459,147	11,683,510
Other assets	1,117	1,117
Total assets	14,460,264	11,684,627
Accounts payable	1,080,962	2,073,149
Accrued liabilities	536,443	1,012,468
Note Payable	413,174	500,903
Total current liabilities	2,030,579	3,586,520
Total liabilities	2,030,579	3,586,520
Common stock, par value $.0001 per share; authorized 400,000,000 shares; issued and outstanding 1,958,245 as of March 31, 2024 and 298,281 as of December 31, 2023, respectively	0	0
Additional paid-in capital	313,481,082	305,350,830
Accumulated deficit	(301,051,593)	(297,252,753)
Total stockholders' equity	12,429,685	8,098,107
Total liabilities and stockholders' equity	14,460,264	11,684,627
Series A Preferred Stock [Member]
Series A Preferred stock, par value $.0001, authorized 5,181,346 shares; issued and outstanding 210, as of March 31, 2024 and December 31, 2023, respectively	$ 196	$ 30

About Tenax Therapeutics Inc

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

CEO	Mr. Christopher T. Giordano
WEBSITE	tenaxthera.com
INDUSTRY	Biotechnology
EMPLOYEES	7

Tenax Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Tenax Therapeutics Inc? What does TENX stand for in stocks?

TENX is the stock ticker symbol of Tenax Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Tenax Therapeutics Inc (TENX)?

As of Fri May 17 2024, market cap of Tenax Therapeutics Inc is 6.95 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TENX stock?

You can check TENX's fair value in chart for subscribers.

What is the fair value of TENX stock?

You can check TENX's fair value in chart for subscribers. The fair value of Tenax Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Tenax Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TENX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Tenax Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether TENX is over valued or under valued. Whether Tenax Therapeutics Inc is cheap or expensive depends on the assumptions which impact Tenax Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TENX.

What is Tenax Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, TENX's PE ratio (Price to Earnings) is 0.67 and Price to Sales (PS) ratio is 0.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TENX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Tenax Therapeutics Inc's stock?

In the past 10 years, Tenax Therapeutics Inc has provided -0.657 (multiply by 100 for percentage) rate of return.